Patient characteristics and data collection
tumor, Tumor, illness, seizure, seizures, epileptic seizure, Seizure, intracranial diseases, 1p19q
EPILEPTIC SEIZURE, TUMOR, TUMOR, MALIGNANT DISEASE
Data from 208 patients who underwent craniotomy and were diagnosed with primary DHGG at Beijing Tiantan Hospital, China, were retrospectively reviewed. Patients who previously underwent surgery for other intracranial diseases or had any other concomitant malignant diseases were excluded from the study. All patients had received the standard treatment, including maximal safe resection and adjuvant radiotherapy and/or chemotherapy, depending on their tumor grade. Demographic data (age and gender) and the main complaints from patients were retrieved from an electronic medical record system. Tumor samples collected during craniotomy were flash frozen in liquid nitrogen and stored at -80 °C. Hematoxylin and eosin staining was performed, and tumor tissues containing > 80% tumor cells were selected for further analysis. Molecular pathological characteristics, including IDH1/2 mutation, chromosome 1p19q co-deletion, and MGMT promoter methylation status were assessed through pyrosequencing or fluorescence, as previously described [Preoperative GRE was defined as at least one unprovoked epileptic seizure prior to surgery based on the patients' main complaint and history of illness. All patients received prophylactic AEDs after surgery, including phenobarbital injections administered within 3 d and valproate or levetiracetam tablets administered for at least 3 months. Seizure outcome was followed up via telephone interviews conducted 12 months after surgery, and postoperative seizure occurrence was defined as at least one unprovoked epileptic seizure occurring between the day of discharge and the day of follow-up. Patients with overall survival time of less than 12 months were excluded from the study. All data analyzed here, except those related to seizures, have been uploaded to the CGGA portal (